Hanmi Pharm. Co., Ltd.

Wook Jang

Kwee Hyun Suh

Tae Hee Ha

Ji Sook Kim

Ji Young Song

Young Ho Moon

Won Jeoung Kim

Nam Du Kim

Moon Sub Lee

The present invention relates to a novel method for preparing thienopyrimidine compound having an activity of selectively inhibiting tyrosine kinase, specifically the mutant epidermal growth factor receptor tyrosine kinase; and a novel intermediate used therein. According to the method of the present invention, the industrial mass-production of the compound of Formula 1, which is useful as a therapeutic agent for non-small cell lung cancer induced by the mutant epidermal growth factor receptor tyrosine kinase, can be implemented more conveniently and efficiently than the conventional technology.

Process for preparing thienopyrimidine compound and intermediates used therein

The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and a pharmaceutical composition including the same as an active ingredient, which effectively inhibit the SGLT activity, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes including insulin-dependent diabetes (type I diabetes mellitus) and non-insulin-dependent diabetes (type II diabetes mellitus), diabetic complications, and obesity.

Bicyclic derivatives and pharmaceutical composition including the same

Growing community of inventors

Hwaseong-si, South Korea

Wook Jang